Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...

Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been ...